This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Nektar Therapeutics Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 02:00 PM
Earnings Flash (NKTR) NEKTAR THERAPEUTICS Reports Q1 Revenue $21.6M, vs. Street Est of $15.3M MT
Nektar Therapeutics Reiterates Earnings Guidance for the Year 2024 CI
Transcript : Nektar Therapeutics, Q1 2024 Earnings Call, May 09, 2024
Nektar Therapeutics Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Biolojic Design Announces Nektar Therapeutics Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases CI
Nektar Therapeutics announced that it has received $30 million in funding from TCG Crossover Management, LLC CI
Nektar Therapeutics Begins Phase 2b Trial for Rezpegaldesleukin in Patients With Severe Alopecia Areata MT
Jefferies Adjusts Nektar Therapeutics Price Target to $1 From $0.50, Maintains Hold Rating MT
Nektar Therapeutics Announces Initiation of Phase 2B Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata CI
Transcript : Nektar Therapeutics, Q4 2023 Earnings Call, Mar 04, 2024
Nektar Therapeutics Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (NKTR) NEKTAR THERAPEUTICS Reports Q4 Revenue $23.9M, vs. Street Est of $21.4M MT
Nektar Therapeutics Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
North American Morning Briefing : Stock Futures -2- DJ
Nektar Therapeutics announced that it expects to receive $30 million in funding from TCG Crossover Management, LLC CI
DiaMedica Therapeutics Names Lorianne Masuoka as Chief Medical Officer MT
Transcript : Nektar Therapeutics Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 05:15 PM
Nektar Therapeutics(NasdaqCM:NKTR) dropped from NASDAQ Biotechnology Index CI
Nektar Therapeutics Reports Positive Preclinical Data on NKTR-255 MT
North American Morning Briefing : Investors Weigh -2- DJ
TD Cowen Upgrades Nektar Therapeutics to Outperform From Market Perform MT
Transcript : Nektar Therapeutics, Q3 2023 Earnings Call, Nov 07, 2023
Earnings Flash (NKTR) NEKTAR THERAPEUTICS Posts Q3 Revenue $24.1M, vs. Street Est of $21.3M MT
Nektar Therapeutics Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Chart Nektar Therapeutics
More charts
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company. The Company is focused on discovering and developing medicines in the field of immunotherapy. The Company has a research and development pipeline of investigational medicines in immunology and oncology. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its pipeline includes NKTR-255, Rezpegaldesleukin (REZPEG) and NKTR-0165. NKTR-255 is an investigational biologic that is designed to target the interleukin-15 (IL-15) pathway in order to activate the body’s innate and adaptive immunity. Its Rezpegaldesleukin pipeline is an investigational, potential first-in-class T regulatory cell stimulator that addresses this underlying immune system imbalance in people with many autoimmune and inflammatory conditions. Rezpegaldesleukin is being developed as a self-administered injection.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
1.16 USD
Average target price
1.6 USD
Spread / Average Target
+37.93%
Consensus
  1. Stock Market
  2. Equities
  3. NKTR Stock
  4. News Nektar Therapeutics
  5. Sector Update: Health Care Stocks Advancing in Late Afternoon Trading